Final Analysis of Neoadjuvant Sintilimab Plus Chemotherapy in IB-IIIA Non-Small-Cell Lung Cancer: Phase 2 neoSCORE Trial.
Cancer SciJun 7, 2026 (epub)
Miner Shao, Jie Yao, Lufeng Zhao et al.
✦ AI-curated · Sources linked
In 30 seconds
The phase 2 neoSCORE trial evaluated the efficacy of two versus three cycles of neoadjuvant sintilimab plus chemotherapy in 60 patients with stage IB-IIIA non-small cell lung cancer. After a median follow-up of 56.9 months, no significant differences in disease-free survival (DFS) or overall survival (OS) were found, with 4-year DFS rates of 53.8% and 55.2%, and OS rates of 76.9% and 75.9%, respectively.
Key findings
- No significant differences in 4-year DFS rates: 53.8% for two cycles vs 55.2% for three cycles.
- 4-year OS rates were 76.9% for two cycles and 75.9% for three cycles.
- Major pathological response (MPR) was associated with improved DFS (HR=0.26) and OS (HR=0.15).
- Maintenance immunotherapy correlated with longer DFS in patients achieving MPR.
Why it matters
Understanding the optimal number of neoadjuvant treatment cycles is crucial for improving patient outcomes in non-small cell lung cancer. This study highlights the importance of MPR as a prognostic factor and suggests potential benefits of maintenance immunotherapy.